There are currently 117 clinical trials in Eugene, Oregon looking for participants to engage in research studies. Trials are conducted at various facilities, including Oregon Research Institute, Willamette Valley Cancer Institute and Research Center, University of Oregon and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Willamette Valley Cancer Institute and Research Center, Eugene, Oregon
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Recruiting
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Local Institution - 0098, Eugene, Oregon
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Willamette Valley Cancer Institute, Eugene, Oregon
Conditions: Low Grade Serous Ovarian Cancer
INHANCE Stemless Reverse Shoulder IDE
Recruiting
2:1 Randomized, Controlled, Multi-Center, Prospective, Pre-Market Study of the INHANCE Stemless Reverse Cementless Total Shoulder.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/27/2025
Locations: Slocum Center for Orthopaedics and Sports Medicine, Eugene, Oregon
Conditions: Arthroplasty, Replacement, Shoulder
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Recruiting
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/26/2025
Locations: Prevention Science Institute, Eugene, Oregon
Conditions: Schizophrenia
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Recruiting
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/26/2025
Locations: Oncology Associates of Oregon, PC, Eugene, Oregon
Conditions: Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Recruiting
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
Gender:
FEMALE
Ages:
15 years and above
Trial Updated:
03/24/2025
Locations: Research Site, Eugene, Oregon
Conditions: Locally Advanced Cervical Cancer
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA)
Recruiting
The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/24/2025
Locations: Verum Research, LLC, Eugene, Oregon
Conditions: Geographic Atrophy
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Recruiting
The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated CLL. This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene, Oregon
Conditions: Chronic Lymphocytic Leukemia
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
Recruiting
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in adult participants in relapsed or refractory (R/R) NHL, including but not limited to diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Adverse events will be assessed. ABBV-291 is an investigational dr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Willamette Valley Cancer Institute and Research Center /ID# 270945, Eugene, Oregon
Conditions: Non-Hodgkin's Lymphoma
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Recruiting
This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2025
Locations: Willamette Valley, Eugene, Oregon
Conditions: NSCLC
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Recruiting
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one GM T cell infusion will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Gender:
ALL
Ages:
All
Trial Updated:
03/21/2025
Locations: Willamette Valley Cancer Institute, Eugene, Oregon
Conditions: Neoplasms